The Food and Drug Administration announced Wednesday that it has granted expedited approval to daraxonrasib, a groundbreaking oral medication for the most common form of pancreatic cancer. The drug, marketed under the brand name Rasonque by Revolution Medicines, targets mutated KRAS proteins that drive tumor growth in more than 90% of pancreatic cancer cases.
How the drug works and trial results
Daraxonrasib acts like a molecular glue, binding to multiple KRAS subtypes and preventing the mutated protein from signaling cells to proliferate. In a company‑funded, randomized study of 500 patients whose metastatic disease had stopped responding to prior therapies, the medication produced a median overall survival of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy. Patients also experienced fewer severe adverse events, though common side effects included skin rash, mouth sores, diarrhea and other digestive issues.
Impact on patients and families
“This is one of the most anticipated approvals I can think of,” said Dr. Andrew Coveler of the Fred Hutch Cancer Center. “The medicine is not a cure but a significant improvement.” Former Senator Ben Sasse, R‑Neb., who has spoken publicly about his own experience with the drug, reported reduced pain and a better quality of life while on treatment, helping raise public awareness and prompting the FDA to allow expanded access before formal approval.
Why this matters for a deadly disease
Pancreatic cancer remains one of the nation’s deadliest cancers, largely because it is often diagnosed after it has spread. The American Cancer Society estimates roughly 67,000 new cases and more than 52,000 deaths in the United States this year, with a five‑year overall survival rate of just 13%. Until now, treatment options have been limited, and many experimental approaches have failed to overcome the so‑called “undruggable” KRAS target.
Broader implications for cancer research
Experts believe the approval could open doors for additional therapies that target KRAS mutations in other tumor types. “I think this has opened doors for many other companies,” said Dr. Pashtoon Kasi of City of Hope Orange County. “Downstream we will see a lot more trials looking at this approach in other cancers.” Revolution Medicines, based in Redwood City, California, is already exploring the technology for lung cancer and other malignancies.
Cost and access considerations
The company disclosed that a one‑month supply of Rasonque will cost approximately $39,800. While the price reflects the drug’s innovative nature, it also raises questions about affordability and insurance coverage for patients and families facing a life‑threatening diagnosis.
Regulatory perspective
Acting FDA Commissioner Kyle Diamantas emphasized the agency’s commitment to delivering meaningful treatments quickly, noting that the approval came more than six months ahead of the FDA’s original target date. “It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” he said in a statement.
With this approval, patients across the United States now have a new therapeutic option that not only extends survival but also offers a more manageable side‑effect profile, marking a significant step forward in the fight against pancreatic cancer.
Original reporting: NBC10 Boston — read the source article.
